Researchers Report Progress in Cellular Age Reversal
New lab data shows 60-year age reversal in blood cells, while human trials for glaucoma treatment show early signs of efficacy.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you believe medical research on reversing cellular aging will significantly improve human health outcomes?
University of Bonn researchers have successfully converted 80-year-old donor blood cells into neural stem cells, documenting a cellular age reversal of 60 years. Concurrently, Life Biosciences reported that two out of three glaucoma patients showed vision improvements following a 56-day treatment with ER-100.
Why it matters
These findings mark a shift from theoretical longevity research to the clinical observation of cellular rejuvenation. Understanding how to systematically reverse cellular age remains the primary hurdle for developing future regenerative medical therapies.
Researchers tracked cellular rejuvenation over a 100-day period, finding that epigenetic clocks—biochemical markers of biological age—confirmed the converted neural cells aged to younger than 20 years. Life Biosciences reported that three glaucoma patients tolerated the ER-100 treatment for 56 days.
The players
University of Bonn
A German research university specializing in experimental biology and epigenetic cellular studies.
Life Biosciences
A biotech firm developing therapies to target the biological causes of aging, specifically using ER-100 for vision-related conditions.
NewLimit
A venture-backed biotechnology startup focused on epigenetic reprogramming to develop treatments for age-related diseases.
The details
The Bonn team utilized a direct conversion method, transforming immature blood cells into neural stem cells while bypassing the traditional intermediate stem-cell state. This approach allowed for the observation of gradual rejuvenation rather than an abrupt shift in cell identity. The ER-100 treatment tested by Life Biosciences is currently the focus of ongoing human evaluation to determine its efficacy in treating degenerative ocular conditions.
Timeline
January 2026: US regulators authorized the testing of ER-100.
June 2026: NewLimit raised $435 million in new capital.
Mid-September 2026: Total investment in longevity biotechnology reached $12.1 billion.
October 8, 2026: Life Biosciences reported initial human trial results.
2027: NewLimit plans to initiate human testing for a liver cell therapy.
The Tech Race
Investment in longevity biotechnology remains intense, with $12.1 billion raised through mid-September 2026 following an $18.4 billion total in 2025. This capital is fueling a competitive race between firms like NewLimit and Life Biosciences to move epigenetic reprogramming from lab experiments to human clinics.
These treatments are currently restricted to clinical trial participants and laboratory research settings, with no immediate commercial availability for the public. Future access depends on successful outcomes in phase trials and subsequent regulatory approvals for specialized therapeutic use.
The takeaway
The field is shifting from identifying markers of aging to demonstrating functional human health improvements through epigenetic intervention. Watch for upcoming phase trial data from NewLimit in 2027 to see if liver-targeted reprogramming achieves similar success to current ocular studies.
What happens next
NewLimit is scheduled to initiate human trials for a new liver cell therapy in 2027.
Further reading
Explore deeper into the current landscape of Biotech to track emerging clinical results.
Source note: This article includes information reported by BeInCrypto.
Live Poll
Do you believe medical research on reversing cellular aging will significantly improve human health outcomes?
